AddedRisk Factors
The EU’s General Data Protection Regulation (the “GDPR”), the CCPA, and the data protection and security laws of other states and countries impose additional requirements with respect to disclosure and deletion of personal information of their residents, imposing penalties for violations and, in some cases, private right of action for data breaches. These laws, and similar legislation that is developing or has been recently enacted, impose transparency and other obligations with respect to personal data of their respective residents and provide residents with similar rights for certain types of data breaches. We have invested, and continue to invest, human and technology resources in our data compliance efforts that may be time-intensive and costly. Despite our efforts, there is a risk that we may be subject to fines and penalties for non-compliance and experience litigation, reputational harm and business interruption if we fail to protect the privacy of third-party data or to comply with the GDPR, CCPA, and other applicable data privacy and protection regimes.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedRisk Factors
with whom we do business may attempt to circumvent our security measures in order to obtain such information and may purposefully or inadvertently cause a breach involving such information. Despite the security measures we have in place and any additional measures we may implement in the future to safeguard our systems and to mitigate potential security risks, our facilities and systems, and those of our third-party service providers, could be vulnerable to security breaches, including the Cyber Incident (as defined below) . If unauthorized parties gain access to our systems or databases, such as with the Cyber Incident, or those of third parties on which we rely, they could be able to steal, publish, delete, hold ransom or modify our private and sensitive information, including payment information, personal information, and confidential and other proprietary business information. The Company, its customers, suppliers and business partners, as well as the Company’s employees, could suffer harm if valuable business data, or employee, customer and other confidential and proprietary information were corrupted, lost, accessed or misappropriated by third parties due to a cyber-attack, a security systems failure, or due to one of our third-party service providers or our employees.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedRisk Factors
Even the most well protected IT networks, systems and facilities remain potentially vulnerable because the techniques used in attempted cybersecurity attacks are continually evolving, and may not be recognized until after the attack is launched against a target or, in some instances, are designed not to be detected and, in fact, may not be detected. Any such compromise of the Company’s or any of our partners’ IT systems could result in unauthorized access, public disclosure, or loss of personal, sensitive, or confidential business information, could result in legal claims and proceedings, liability under applicable laws and regulatory penalties, and could disrupt the Company’s operations, require significant management attention and resources to remedy any damages that result, and damage the Company’s reputation and customer willingness to transact business with it, any of which could adversely affect its business.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedRisk Factors
We experienced a material information technology (“IT”) systems incident in February 2026, which could result in a number of potentially unknown outcomes, including but not limited to, litigation, regulatory investigations or enforcement actions, or reputational harm, any of which could have a material impact on our business operations, financial condition, or results of operations.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
Two customers (Intuitive Surgical SARL and Stryker) comprised approximately 28.8% 24.3% and 21.5%, respectively, of our net sales for the year ended December 31, 2025; two customers (Intuitive Surgical SARL and Stryker) comprised approximately 29.2% and 15.4%, respectively, of our net sales for the year ended December 31, 2024; one customer comprised approximately 28.1% of our net sales for the year ended December 31, 2023; and one customer comprised approximately 21.5% of our net sales for the year ended December 31, 2022. 2023.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
These risks Changes in foreign currency rates could have a material adverse effect on our business, financial position, results of operations, financial condition, and cash flows, and could materially harm our reputation. flows.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
If our suppliers choose to expand their own operations, through acquisitions or otherwise, and begin manufacturing and selling products directly to our customers, it could reduce our pricing or sales volume and overall profitability.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our top ten customers represented approximately 68.8%, 68.1%, 59.3%, and 47.2% 59.3% of our total net sales in 2025, 2024, and 2023, and 2022, respectively.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
At December 31, 2024, 2025, we had $334 $338.3 million of goodwill and other intangible assets, representing approximately 53% 51.6% of our total assets.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Increased competition for the sales of our products could result in price reductions, reduced margins, and loss of market share, which could materially adversely affect our prospects, business, financial condition and results of operations.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
In 2025, we executed a post-acquisition review of our AJR labor force’s United States employment eligibility through E-Verify protocols. This review has resulted in significant workforce turnover during the year (the "AJR Labor Issue"). Attention spent by experienced employees training new direct and indirect employees in our standards and policies has decreased productivity and therefore, has created inefficiencies in our AJR operations. To address the AJR Labor Issue, we recruited legally eligible replacement associates. We estimate that the AJR Labor Issue added over $6.3 million in incremental labor cost to our cost-of-sales for year ended December 31, 2025.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
In 2025, the United States imposed increased tariffs on foreign imports into the United States, including all the countries in which we manufacture goods outside the United States and also the countries in which our customers operate. Although agreements have been made with various countries, the tariff policy environment remains dynamic, particularly in light of recent Supreme Court decisions, and we cannot predict what additional actions may ultimately be taken by the United States or other governments with respect to tariffs or trade relations, including retaliatory trade measures taken by other countries in response to existing or future United States tariffs or other measures. We estimate that tariffs not reimbursed by customers were immaterial to our 2025 results.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
On or about February 14, 2026, the Company detected the Cyber Incident (as defined in Item 1C, Cybersecurity). As of the date hereof, the incident has not had a material impact on the Company’s financial systems, operations or financial condition. While the Company’s investigation and assessment of this incident is ongoing, as of the date of this filing, the Company believes its primary IT systems are operational in all material respects and the Company does not believe the incident is reasonably likely to materially impact the Company’s financial condition or results of operations. There can be no assurance that the Cyber Incident or any future cybersecurity incidents will not have a material impact on the Company’s future operations, financial systems or financial condition. See Item 1A “Risk Factors” under the headings “Security breaches, including cybersecurity incidents and other disruptions could compromise our information, expose us to liability and harm our reputation and business” and “We experienced a material information technology (“IT”) systems incident in February 2026, which could result in a number of potentially unknown outcomes, including but not limited to, litigation, regulatory investigations or enforcement actions, or reputational harm, any of which could have a material impact on our business operations, financial condition, or results of operations,” and the discussion in Item 1C, Cybersecurity.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
In connection with the acquisitions of Welch and Marble in 2024, and DAS Medical in 2021, we are required to make contingent payments, subject to the entities achieving certain financial performance thresholds. The total potential contingent consideration payments for the Welch, Marble and DAS Medical acquisitions were $6.0 million, $0.5 million,
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
On July 4, 2025, President Donald Trump signed the “One Big Beautiful Bill Act” (OBBBA) into law, which is considered the enactment date under U.S. GAAP. Key corporate tax provisions include the restoration of 100% bonus depreciation, immediate expensing for domestic research and experimental expenditures, changes to Section 163(j) interest limitations, updates to GILTI and FDII rules, amendments to energy credits, and expanded Section 162(m) aggregation requirements. In accordance with ASC 740, the effects of the new tax law have been recognized in the period of enactment. The impact of OBBBA to our income tax expense is immaterial.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RemovedMD&A
The Company completed four strategic acquisitions during the year ended December 31, 2024. The acquired operations primarily serve the medical market and contributed to an overall 26.1% increase in net sales for the year. Organic net sales grew 8.5%, fueled by strong sales in the robotic surgery and infection prevention markets. Net sales relating to our largest customer, Intuitive Surgical SARL, were 28.8% of our net sales for the year ended December 31, 2024. This increase in net sales as well as strong margins and the leverage of relatively fixed SG&A costs, allowed the Company to generate a 40.3% and 31.3% increase in operating income and net income, respectively, for the year ended December 31, 2024.
Read it in 10-K Mar 3, 2025 at sec.govopen_in_new
RemovedMD&A
These cash inflows and adjustments to income were partially offset by an increase in inventory of approximately $4.7 million due to inventory build for upcoming demand, an increase in prepaid expenses of approximately $0.5, an increase in refundable income taxes of approximately $3.4 million due to conservative estimated tax payments in in 2024, a decrease in accounts payable of approximately $1.1 million due to the timing of vendor payments in the ordinary course of business, a decrease in deferred revenue of approximately $1.9 million due to the recognition of development revenue and a decrease in other long-term liabilities of approximately $6.5 million due primarily to non-compete payments and payments of contingent consideration.
Read it in 10-K Mar 3, 2025 at sec.govopen_in_new
RemovedMD&A
The Company accounts for treasury stock under the cost method, using the first-in, first-out cost flow assumption, and includes treasury stock as a component of stockholders’ equity. On June 16, 2015, the Company announced that its Board of Directors authorized the repurchase of up to $10.0 million of the Company’s outstanding common stock. Under the program, the Company is authorized to repurchase shares through Rule 10b5-1 plans, open market purchases, privately negotiated transactions, block purchases or otherwise in accordance with applicable federal securities laws, including Rule 10b-18 of the Securities Exchange Act of 1934. The stock repurchase program will end upon the earlier of the date on which the plan is terminated by the Board or when all authorized repurchases are completed. The timing and amount of stock repurchases, if any, will be determined based upon our evaluation of market conditions and other factors. The stock repurchase program may be suspended, modified or discontinued at any time, and the Company has no obligation to repurchase any amount of its common stock under the program. There were no share repurchases during the years ended December 31, 2024, 2023, and 2022. At December 31, 2024, approximately $9.4 million was available for future repurchases of the Company’s common stock under this authorization.
Read it in 10-K Mar 3, 2025 at sec.govopen_in_new
RemovedMD&A
We base the fair value of identifiable intangible assets acquired in a business combination on detailed valuations that use information and assumptions provided by management, which consider management’s best estimates of inputs and assumptions that a market participant would use. Further, for those arrangements that involve potential future contingent consideration, we record on the date of acquisition a liability equal to the fair value of the estimated additional consideration we may be obligated to pay in the future. We remeasure this liability each reporting period and record changes in the fair value through a separate line item within our consolidated statements of comprehensive income. Increases or decreases in the fair value of the contingent consideration liability can result from changes in discount rates, periods, timing and amount of projected revenue or timing or likelihood of achieving regulatory, revenue or commercialization-based milestones. The use of alternative valuation assumptions, including estimated revenue projections, growth rates, cash flows, discount rates, useful life or probability of achieving clinical, regulatory or revenue-based milestones could result in different purchase price allocations and recognized amortization expense and contingent consideration expense or benefit in current and future periods.
Read it in 10-K Mar 3, 2025 at sec.govopen_in_new
RewordedMD&A
Net cash provided by operations for the year ended December 31, 2024 2025 was approximately $66.6 $91.9 million and was primarily a result of net income generated of approximately $59.0 $68.3 million, depreciation and amortization of approximately $14.7 $19.2 million, and share-based compensation of approximately $6.8 million, a change in $8.9 million for the fair value of contingent consideration of approximately $1.0 million, an increase in net deferred income tax liabilities of approximately $ 1.3 million, a decrease in accounts receivable of approximately $1.2 million due to the collection of an escrow receivable, and a decrease in other assets of approximately $0.6 million. year ended December 31, 2025.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
Net cash used in investing activities for the year ended December 31, 2024 2025 was approximately $210.2 $27.6 million and was primarily the result of the acquisition of Marble Medical, AJR Enterprises, Welch Fluorocarbon, and AQF Medical, and the additions of manufacturing machinery and equipment and various building improvements across improvements, as well as the Company. acquisitions of AJR Specialty, AJR Custom Foam, TPI, and UNIPEC.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
Selling, General, and Administrative Expenses (“SG&A”) increased approximately 22.3% 24.5% to $62.2 $77.4 million for the year ended December 31, 2024, 2025, from $50.9 $62.2 million in 2023, largely due to SG&A from the Company’s recent acquisitions as well as increased performance-based compensation and professional fees. 2024.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
As a percentage of net sales, SG&A decreased increased to 12.3% 12.8% for the year ended December 31, 2024, 2025, from 12.7% 12.3% for the same period in 2023 reflecting the leverage of the net sales increase over relatively fixed SG&A. last year.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
The Company believes We do not believe that any of the following critical significant accounting policy necessitated that policies required significant judgments judgment and estimates be used in the preparation of its our consolidated financial statements.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
Net sales increased 26.1% to $504.4 million for the year ended December 31, 2024, 2025 increased 19.5% to $602.8 million from net sales of $400.1 $504.4 million for in the same period in 2023. last year.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
For more information about the Company’s results of operations of 2023 2024 compared to 2022, 2023, see the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations - — Results of Operations - 2023 — 2024 Compared to 2022” 2023” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, 2024, filed with the SEC on February 29, 2024. March 3, 2025.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
Other income was approximately $189 thousand and other expense was approximately $117 thousand $0.2 million for the years year ended December 31, 2024 and 2023, respectively. 2024.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
The Company is an important We are a vital link in the medical device supply chain and a valued outsource outsourcing partner to many of the world's top medical device manufacturers in the world. manufacturers.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
The Company We incurred approximately $2.5 $0.3 million in costs associated with acquisition related activities which were charged to expense for the year ended December 31, 2025, as compared to $2.5 million for the year ended December 31, 2024.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
The change in fair value of contingent consideration for the acquisitions for the year ended December 31, 2024, resulted in an expense of approximately $1.0 million, and is included in change in fair value of contingent consideration in the condensed consolidated statements of comprehensive income.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
The Company had net Net interest expense of was approximately $8.1 $9.8 million and $3.6 $8.1 million for the year years ended December 31, 2024 2025 and 2023, 2024, respectively.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new